Olanzapina Stada (Olanzapine)

Olanzapine is an atypical antipsychotic that modulates neurotransmitter activity in psychotic and mood disorders.

• Schizophrenia: Reduces positive and negative symptoms and helps maintain stability.
• Bipolar I disorder: Controls acute manic episodes and supports long‑term mood stabilization.
• Psychotic depression: Alleviates depressive symptoms with psychotic features when combined with antidepressants.

• Olanzapine blocks several neurotransmitter receptors, notably dopamine D2 and serotonin 5‑HT2A/2C receptors, while also affecting histamine H1, muscarinic, and adrenergic receptors. This broad receptor antagonism reduces dopaminergic overactivity and modulates serotonergic pathways, contributing to antipsychotic and mood‑stabilising effects.

Olanzapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Weight gain: Increased appetite leading to moderate weight increase.
• Sedation: Drowsiness or feeling of being slowed down.
• Dry mouth: Reduced salivation causing oral discomfort.
• Constipation: Decreased bowel motility.
• Elevated triglycerides: Mild rise in blood lipid levels.
• Orthostatic hypotension: Light‑headedness on standing.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: Potentially life‑threatening reaction with fever and muscle rigidity.
• Tardive dyskinesia: Persistent involuntary movements, often of the face.
• Hyperglycaemia: Significant rise in blood glucose, may precipitate diabetes.
• Seizures: Increased risk of convulsive episodes.
• Agranulocytosis: Marked reduction in white‑blood cell count.
• Hepatotoxicity: Liver enzyme elevations indicating possible injury.

When prescribing Olanzapina Stada, clinicians should consider several safety aspects.

• Monitor metabolic parameters: Regularly check weight, fasting glucose, and lipid profile.
• Assess for movement disorders: Observe for signs of tardive dyskinesia or extrapyramidal symptoms.
• Evaluate cardiovascular status: Watch for orthostatic hypotension and ECG changes.
• Review hepatic function: Periodic liver‑function tests are advisable.
• Pregnancy and lactation: Use only if benefits outweigh risks; discuss with obstetric specialist.
• Store at below 25°C: Keep in the original packaging, protect from moisture and direct sunlight.

Olanzapine can interact with several drug classes, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP1A2 inhibitors (e.g., fluvoxamine): May increase olanzapine plasma levels.
• CNS depressants (e.g., benzodiazepines, opioids): Additive sedation and respiratory depression risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., carbamazepine, rifampicin): May reduce olanzapine concentrations.
• Antihypertensives: Potential for enhanced hypotensive effect.
• Anticholinergic agents: May worsen dry mouth and constipation.
• Lithium: May increase risk of neurotoxicity.
• Smoking: Induces CYP1A2, potentially lowering olanzapine exposure.